The FDA GLP-1 Shortage of 2022 to 2024: A Documentary Timeline

For healthRX’s complete compounded semaglutide guide, the useful starting point is not whether the internet is excited about it. It is whether the evidence, safety limits, prescription pathway, and follow-up plan are strong enough to support a real patient decision.

In September 2023, Laura Chen, a primary care physician in suburban Phoenix, started keeping a whiteboard tally in her break room. It tracked the number of patients per week she had to tell that their semaglutide prescription couldn’t be filled at any local pharmacy. By mid-October, the number hit 34 in a single week. “I had patients crying in the exam room,” she told a colleague. “Not because the drug didn’t work. Because they couldn’t get it.”

Laura’s whiteboard tells the story of the GLP-1 shortage better than any FDA press release. What happened between 2022 and early 2025 was a slow-rolling supply crisis that reshaped how patients, prescribers, and pharmacies think about injectable weight loss medications. This is a documentary timeline of that crisis, what it revealed, and what it means now.

Demand Outran the Forecast

In late 2021, prescription volume for branded semaglutide started climbing faster than Novo Nordisk had projected. Off-label prescribing for weight loss was accelerating well ahead of Wegovy’s formal commercial rollout, and supply allocations that had seemed comfortable through 2020 were thinning. By early 2022, pharmacy trade publications were reporting regional shortages. The signals were there if you were paying attention.

A 2023 analysis published in JAMA Health Forum found that total GLP-1 agonist prescriptions in the United States grew by over 300% between January 2020 and December 2022, with semaglutide accounting for the majority of that increase (Tichy et al., JAMA Health Forum, 2023). Social media played a measurable role. Celebrity endorsements and viral TikTok content about “Ozempic for weight loss” drove patient inquiries that outpaced anything the traditional pharmaceutical marketing apparatus had produced. Endocrinologists and obesity medicine specialists reported being overwhelmed with new patient requests, many from individuals who had no prior relationship with a weight management clinic.

The boring truth is that pharmaceutical manufacturing capacity doesn’t scale like software. You can’t spin up a new fill-finish line in a quarter. Sterile injectable production requires validated facilities, FDA inspection, months of stability data. When demand doubles in a year, the factory doesn’t double with it. Novo Nordisk invested over $6 billion in manufacturing expansion between 2022 and 2024, but the timeline from capital expenditure to finished vials is measured in years, not quarters.

March 2022: The Shortage Becomes Official

The FDA placed semaglutide injection on its formal drug shortage list in March 2022. That designation is more than bureaucratic bookkeeping. It has legal teeth. Specifically, it opened the regulatory door for compounding pharmacies operating under 503A and 503B authority to prepare semaglutide formulations on a temporary basis, provided they sourced active pharmaceutical ingredient from FDA-registered facilities.

This is a critical distinction, and one that most patients (and frankly, a lot of media coverage) got wrong. A compounded preparation from a state-licensed pharmacy using FDA-registered API is a fundamentally different product than a vial bought off a sketchy peptide website. More on that in a moment.

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a licensed pharmacist can compound a medication pursuant to a valid individual prescription when a commercial product is in shortage. Under 503B, an outsourcing facility can produce larger batches under more stringent current Good Manufacturing Practice (cGMP) conditions, with FDA oversight that includes regular inspection and adverse event reporting. Both pathways impose real obligations. Neither is a free-for-all.

The Counterfeit Problem

One of the genuinely alarming developments during this period was the flood of unregulated peptide preparations marketed online as semaglutide. Some were sourced from unregistered foreign facilities. Some were labeled “research use only,” which is a polite way of saying they were never intended for human injection. The FDA issued multiple advisories. Several state attorneys general took enforcement action against specific sellers.

In December 2023, the FDA reported that it had identified counterfeit Ozempic pens in the U.S. drug supply chain, some containing insulin rather than semaglutide. That is not a labeling error. That is a clinical emergency waiting to happen. A patient injecting what they believe is semaglutide but is actually insulin faces the risk of severe hypoglycemia, seizures, or death.

Here’s the thing: the counterfeit problem didn’t emerge because compounding pharmacies existed. It emerged because patients were desperate and supply was constrained. People who couldn’t get a prescription filled through normal channels went looking for alternatives. Some of those alternatives were dangerous. The clinical lesson was straightforward but important: provenance matters, sourcing matters, and “semaglutide” on a label doesn’t mean the same thing across every seller.

The practical implication for patients was this: if a product arrives without a prescription, without a pharmacy label, without verifiable lot numbers, or from a seller that cannot produce state licensure documentation, treat it as suspect regardless of price or packaging.

2023: The Shortage Deepens

Through 2023, the shortage broadened rather than resolved. Anti-obesity prescriptions kept climbing. Branded supply remained constrained at specific dose strengths (the 1.0 mg and 1.7 mg doses were particularly hard to find for stretches). Compounded semaglutide moved from a niche option into a meaningful share of total GLP-1 prescription volume in the United States.

A survey conducted by the National Community Pharmacists Association in mid-2023 found that 62% of independent pharmacies reported being unable to fill at least one GLP-1 agonist prescription per week due to supply constraints. In some states, particularly across the Sun Belt, wait times for branded semaglutide stretched to six or eight weeks. Patients who had achieved meaningful weight loss and metabolic improvement found themselves facing involuntary treatment interruptions, with predictable consequences. Clinical data on GLP-1 cessation consistently shows significant weight regain within weeks of discontinuation (Wilding et al., Diabetes, Obesity and Metabolism, 2022), making supply gaps more than an inconvenience. They were therapeutic setbacks.

State boards of pharmacy started issuing their own guidance on documentation standards for compounded preparations. The FDA published a series of additional advisories. The overall effect was a kind of forced maturation: compounding pharmacies that wanted to stay in this space had to raise their documentation, sterility testing, and communication standards significantly. Facilities that had previously operated with minimal quality infrastructure either improved or exited the market under regulatory pressure.

Late 2024 Into 2025: The Shortage Winds Down

Branded manufacturers expanded production capacity through 2024. By early 2025, the FDA began signaling that the formal shortage resolution was approaching. The agency published guidance for compounders, including transition timelines and documentation expectations.

For patients, this created a new kind of difficult conversation. If you’d been stable on a compounded preparation for 12 or 18 months, with good tolerability and steady progress, the question of whether to switch to a branded product wasn’t simple. Dose strengths needed matching. Titration history mattered. A patient who had carefully worked up to a specific dose over months shouldn’t be abruptly transitioned without clinical thought.

Consider a specific scenario: a patient titrated to 1.25 mg weekly of compounded semaglutide with documented tolerability and a 14% total body weight loss over ten months. The branded pen products come in fixed-dose increments (0.25, 0.5, 1.0, 1.7, 2.4 mg for Wegovy). There is no 1.25 mg pen. Switching this patient to a 1.0 mg pen means a dose reduction. Switching to 1.7 mg means a 36% dose increase. Neither is a smooth transition. The prescriber has to evaluate the clinical picture, discuss options, and document the rationale. That takes time and clinical judgment, not a blanket policy memo.

The best prescribers handled this with individual conversations, documented rationale, and defined timelines. The worst sent out form letters.

What the Shortage Actually Taught Us

I think the 2022 to 2024 shortage will be studied in pharmacy schools for years, and not just as a supply chain case study. It revealed several things simultaneously.

First: patient demand for a genuinely effective medication can overwhelm commercial manufacturing capacity in months, not years. The pharmaceutical industry’s demand forecasting models were built for a world where new drugs ramp slowly. GLP-1 agonists broke that assumption. A report from IQVIA estimated that U.S. GLP-1 agonist spending exceeded $24 billion in 2023, a figure that surprised even bullish analysts.

Second: compounding pharmacies, when operating within their legal framework and sourcing from FDA-registered suppliers, function as a real and necessary release valve during documented shortages. They are not an everyday substitute for approved commercial products, but they filled a gap that would have otherwise left hundreds of thousands of patients without access.

Third (and this is the opinionated take): the field dramatically underestimated how much patient education about the regulatory distinction between branded and compounded preparations actually matters. Before the shortage forced this conversation into exam rooms and pharmacy counters, most patients had never heard the terms “503A” or “503B.” Now many of them know more about compounding regulation than their insurance company’s prior authorization department does.

The Post-Shortage Landscape

The post-shortage period is not a return to 2020. Prescription volume is dramatically higher. The patient population is broader and more diverse. Insurance coverage decisions have evolved (in some cases favorably, in many cases not). State boards of pharmacy have updated inspection priorities. Documentation standards across the compounding sector are more rigorous than before the shortage.

For patients starting therapy now, the practical questions have shifted. Where is the medication being prepared? What is the sterility testing protocol? What does the prescribing relationship look like over a full year? These questions matter whether the drug comes from a 503A pharmacy, a 503B outsourcing facility, or a commercial manufacturer.

Supply chain resilience still matters, too. A patient who depends on weekly injections for chronic weight management needs reliable access. The shortage reminded everyone, patients, prescribers, pharmacies, that reliable access is not automatic. It has to be built and maintained. Reputable programs have responded by building inventory transparency, communication protocols, and contingency planning into their operations. Programs like HealthRX, which holds LegitScript certification, represent the kind of verified, transparent operation that patients should look for when evaluating any medication access platform.

Where to Go Deeper

Anyone wanting a more comprehensive treatment of the underlying medication, including dosing, titration, and what to expect from treatment, can review HealthRX’s complete compounded semaglutide guide. It’s structured around the same questions a careful patient would ask in a first visit.

What Comes Next

The literature is still catching up to the clinical reality. Five-year follow-up data are accumulating. Long-term retention curves are starting to appear in published form. Comparative outcomes across different programs and preparation types are being studied. Patients starting therapy now are, in a real sense, contributing to that evidence base. The clinical recommendations of 2028 will look different from those of 2025.

The shortage is winding down. The questions it raised are not. Make decisions with your prescribing clinician, with documented rationale, and with a clear view of what the evidence actually says (rather than what a social media ad implies).

Frequently Asked Questions

What does it mean when the FDA lists a drug as “in shortage”? The FDA maintains a formal database of drug shortages. When a medication is listed, it means the total supply of all versions of that drug is insufficient to meet current demand. For patients, the immediate effect is that pharmacies cannot reliably fill prescriptions. For the regulatory landscape, the listing activates provisions under federal law that allow compounding pharmacies to prepare the drug under 503A and 503B authority, provided they meet specific sourcing and quality requirements.

Is compounded semaglutide legal? Yes, during a documented FDA shortage, licensed compounding pharmacies operating under Section 503A (individual prescriptions) or 503B (outsourcing facility) of the Federal Food, Drug, and Cosmetic Act may prepare compounded semaglutide using API sourced from FDA-registered facilities. The legality is tied to the active shortage designation, applicable state pharmacy law, and compliance with federal compounding regulations. When the shortage resolves, the regulatory framework changes, and compounders must follow FDA transition guidance.

How is compounded semaglutide different from branded Ozempic or Wegovy? Branded products are manufactured by Novo Nordisk under an approved New Drug Application, with standardized dosing, delivery devices, and specific inactive ingredients. Compounded semaglutide uses the same active molecule but is prepared by a pharmacy in a different formulation, typically a multi-dose vial rather than a prefilled pen. Compounded preparations do not undergo the same FDA approval process as branded drugs, though 503B facilities are subject to FDA inspection and cGMP requirements.

What happened with counterfeit semaglutide during the shortage? The FDA identified multiple instances of counterfeit and substandard products entering the market during the shortage. Some products sold online as semaglutide contained no active ingredient, incorrect concentrations, or entirely different substances (including insulin). The agency issued safety alerts and worked with state regulators to take enforcement action. Patients can reduce risk by only obtaining medications through licensed pharmacies with verifiable credentials.

If I was stable on compounded semaglutide, do I have to switch to a branded product now? That decision should be made between you and your prescribing clinician based on your clinical situation. Factors include your current dose, tolerability, insurance coverage, and the specific branded dose strengths available. There is no universal clinical requirement to switch, but the regulatory environment around compounding authority changes when a shortage resolves. Your prescriber should document the rationale for whatever path you follow.

How can I verify that a pharmacy or telehealth platform is legitimate? Look for state pharmacy licensure, which is publicly searchable through your state board of pharmacy’s website. For telehealth platforms, LegitScript certification is a meaningful third-party verification. Ask whether the pharmacy conducts third-party sterility and potency testing on compounded preparations, and whether those results are available upon request. If a seller cannot or will not provide licensure documentation, that is a disqualifying signal.

Will the shortage happen again with other medications? It is possible. The structural conditions that created the GLP-1 shortage, specifically rapid demand growth for a biologic or sterile injectable with limited manufacturing capacity, exist for other drug classes. Tirzepatide (Mounjaro/Zepbound) experienced its own supply constraints during 2023 and 2024. The FDA has acknowledged that its shortage monitoring and communication systems need improvement, and industry analysts expect periodic supply disruptions for high-demand specialty medications to continue.

Not FDA-approved. HealthRX is not a medical practice. Individual results vary.